84.2%
UK licensing authoritiesRisankizumabustekinumabustekinumab-naiveustekinumab-exposedCrohn’s diseaseCD
…t inhibitor which received approval for Crohn’s disease (CD) by UK licensing authorities in May 2023. Our aim was to evaluate the real-world outcomes of…